This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
Discussing Evaporative Dry Eye: Incorporating New Treatments Into Practice (CME/CE)
MedEdicus Podcasts
24 minutes
1 year ago
Discussing Evaporative Dry Eye: Incorporating New Treatments Into Practice (CME/CE)
Access the disclosures, evaluation, and your CME credit via: https://courses.mededicus.com/content/discussing-evaporative-dry-eye-incorporating-new-treatments-practice-cmece-podcast This podcast with Dr. Ken Beckman and Dr. Jaclyn Garlich delves into presentation and treatments of evaporative dry eye primarily caused by meibomian gland dysfunction (MGD). It explores the multifactorial nature of dry eye disease (DED), emphasizing the significance of MGD-driven DED, characterized by a deficien...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
